Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML

May 14, 2024

https://www.globenewswire.com/news-release/2024/05/14/2881267/35186/en/Kura-Oncology-Completes-Enrollment-in-Registration-Directed-Trial-of-Ziftomenib-in-NPM1-Mutant-AML.html

– Company enrolls 85 patients with R/R NPM1-mutant AML in fewer than 16 months –

– Topline data expected in early 2025 –

– Breakthrough Therapy Designation to enable expedited review by FDA –

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.